Jump to ContentJump to Main Navigation
Stem Cell DialoguesA Philosophical and Scientific Inquiry Into Medical Frontiers$
Users without a subscription are not able to see the full content.
Stem Cell Dialogues: A Philosophical and Scientific Inquiry Into Medical Frontiers

Sheldon Krimsky

Print publication date: 2015

Print ISBN-13: 9780231167482

Published to Columbia Scholarship Online: November 2015

DOI: 10.7312/columbia/9780231167482.001.0001

Show Summary Details
Page of

PRINTED FROM COLUMBIA SCHOLARSHIP ONLINE (www.columbia.universitypressscholarship.com). (c) Copyright University of Minnesota Press, 2021. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in CUPSO for personal use.date: 05 August 2021

A Clinical Trial for Paralysis Treatment

A Clinical Trial for Paralysis Treatment

Chapter:
(p.181) Dialogue 25 A Clinical Trial for Paralysis Treatment
Source:
Stem Cell Dialogues
Author(s):

Sheldon Krimsky

Publisher:
Columbia University Press
DOI:10.7312/columbia/9780231167482.003.0025

This dialogue is a fictional account of science reporter Valerie Legere's interview with Dr. Fred Lincoln, a medical doctor working for Geron Corporation of Menlo Park, California. Geron was the first company in the United States to have an investigative new drug (IND) involving stem cells approved for a clinical trial on patients with acute spinal cord injury. Lincoln is overseeing the trial. Dr. Rebecca Franklin has been a short-term consultant to Geron on the ethics and science of the clinical trials because of her work on stem cells for repairing her father's spinal cord injury. Here Lincoln talks to Legere about the risks and benefits of the trial, how the trial works, the form of stem cell therapy that trial participants will receive, positive and negative outcomes expected from the trial and the precautions that Geron has been taking to prevent negative outcomes, and why the Food and Drug Administration stopped Geron's first trial in 2009.

Keywords:   investigative new drug, stem cells, spinal cord injury, ethics, clinical trials, stem cell therapy, Food and Drug Administration

Columbia Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs, and if you can't find the answer there, please contact us .